Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.51 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867027 | 0.86 | VCAM1 (0.53) | VCAM1ACLYSLC22A12PTGDR2PLA2G7 | |
| SCHEMBL1156201 | 0.85 | TRPV4 (0.50) | VCAM1SLC22A12TRPV4 | |
| SCHEMBL1941288 | 0.84 | EPAS1 (0.41) | VCAM1SLC22A12TRPV4MEN1ALDH1A1 | |
| SCHEMBL4195364 | 0.83 | EPAS1 (0.51) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL27860750 | 0.82 | ALDH1A1 (0.37) | VCAM1ACLYPTGDR2ALDH1A1 | |
| SCHEMBL2392684 | 0.80 | VCAM1 (0.47) | VCAM1ACLYSLC22A12PTGDR2ALDH1A1 | |
| SCHEMBL25366711 | 0.79 | TSHR (0.41) | SLC22A12PTGDR2MEN1ALDH1A1KMT2A | |
| SCHEMBL20870724 | 0.79 | XDH (0.40) | TRPV4MEN1ALDH1A1KMT2A | |
| SCHEMBL319459 | 0.79 | ACLY (0.47) | ACLYSLC22A12PTGDR2TRPV4GRM4 | |
| SCHEMBL320675 | 0.79 | GRM4 (0.38) | VCAM1ACLYSLC22A12TRPV4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | VANDERBILT UNIVERSITY | 2023-09-28 | — | — | US | disclosed |
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150526-A1 | COMPETITIVE AND NONCOMPETITIVE OCTAHYDROCYCLOPENTA[C]PYRROLE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| WO-2014181287-A1 | HETEROCYCLYL COMPOUNDS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2014-11-13 | — | — | WO | disclosed |
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG | 2014-10-16 | — | — | US | disclosed |
| US-8791256-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20100210610-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-19 | — | — | US | disclosed |
| US-20100204225-A1 | Organic compounds | BALA KAMLESH JAGDIS | 2010-08-12 | — | — | US | disclosed |
| US-7666878-B2 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| US-20080312230-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1963317-A1 | USE OF PYRROLO [2 , 3-B]PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309254-A1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | HRH2, QDPR, AVPR2 | VCAM1 4069/4885ACLY 1974/4885SLC22A12 3218/4885 |
| US-20100210610-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | VCAM1 4112/4885ACLY 1652/4885SLC22A12 1323/4885 |
| US-20080114022-A1 | (1-Benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid; chemoattractant receptor-homologous molecule expressed on helper T-cells antagonist; antiinflammatory agent, antiallergen; obstructive airways disease | CCR1, CCL2, CCL11 | VCAM1 130/4885ACLY 4782/4885SLC22A12 3038/4885 |
| US-20100204225-A1 | Organic compounds | SLC10A6, SLCO1B3, OPRM1 | VCAM1 4112/4885ACLY 1652/4885SLC22A12 1323/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | VCAM1 4509/4885ACLY 1/4885SLC22A12 706/4885 |
| US-20230303552-A1 | ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS | CHRM5, CHRM1, CHRM2 | VCAM1 1462/4885ACLY 2760/4885SLC22A12 4352/4885 |
| US-20080312230-A1 | Organic Compounds | OPRM1, OPRL1, OPRD1 | VCAM1 3868/4885ACLY 1921/4885SLC22A12 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.